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Acute respiratory distress syndrome (ARDS) is a challenging disease where inappropriate treatment has the potential to propagate lung injury and causes additional harm as does the lack of appropriate treatment.

According to the most recent definition, ARDS has been classified into mild, moderate, and severe disease based on partial pressure of arterial O~2~ (PaO~2~) and the percentage of O~2~ in the inhaled gas (FiO~2~) ratios (P/F).\[[@ref1]\] Mild ARDS is defined as P/F ratio \>200 mm Hg, but \<300 mm Hg with peak end-expiratory pressure (PEEP), or continuous positive airway pressure of 5 cm H~2~O. Moderate ARDS is defined as P/F ratio \>100 mm Hg, but \<200 mm Hg with PEEP of 5 cm H~2~O. A P/F ratio below 100 mm Hg with PEEP of 5 cm H~2~O is categorized as severe ARDS. The definition also requires that the condition has to occur within 1-week from a known clinical insult or from the onset of respiratory distress.

Substantial progress has been made in the understanding of the pathogenesis of the disease, and different treatment strategies have been proposed accordingly. However, most of them have been unsuccessful in reducing mortality. Only two strategies have shown consistent success in this regard. These are lung-protective ventilation and fluid-conservative therapy.\[[@ref2][@ref3][@ref4]\] More recently, two other strategies have been successful in reducing the mortality of ARDS. The first is a strategy of prone-positioning patients with moderate to severe ARDS (defined by P/F \< 150). The second strategy uses neuromuscular blockers while the patients are mechanically ventilated. The 2010 ARDS et Curarisation Systematique trial demonstrated the benefits of using Cisatracurium for 48 h in ARDS patients with P/F ratios below 150.\[[@ref5]\] The 2013 Proning Severe ARDS Patients trial prone-positioned ARDS patients with moderate to severe ARDS and demonstrated its beneficial effects on 28- and 90-day mortality.\[[@ref6]\] There are multiple explanations as to why prone-positioning improves mortality. We now know that it is the reduction in ventilator-induced lung injury and not the improvement in hypoxemia that saved lives.\[[@ref7]\] The use of inhaled pulmonary vasodilators and extracorporeal membrane oxygenation has been applied to treat severe ARDS, but their use can only be justified in the most severe hypoxemic patients who are refractory to usual management strategies.\[[@ref8]\]

In spite of these advances, mortality continues to be high all over the world. Have these advancements been able to make a major impact on the absolute mortality figures? Unfortunately, the answer is no. The incidence and overall mortality of ARDS have not changed substantially over the last 10 to 15 years, and the current mortality of adult ARDS is still greater than 40%.\[[@ref9][@ref10][@ref11]\] Does this indicate that there is an elusive aspect of ARDS management that has been ignored? There are multiple possible answers, but none emerges a clear winner.

One of the promising theories that have been proposed as an explanation for the above-mentioned phenomenon is based on the finding that a significant number of patients with ARDS have acute cor pulmonale (ACP). ACP has been associated with poor outcomes in other clinical situations, one of which is pulmonary embolism, and similar outcomes would not be entirely unexpected in ARDS. Unfortunately, very little has been done about it. It is high time that we recognized the occurrence of pulmonary vascular dysfunction and ACP in ARDS patients and the detrimental impact on outcomes. It is difficult to diagnose pulmonary vascular dysfunction without taking recourse to use pulmonary artery catheters (PACs), which fortunately is not the standard of care in most Intensive Care Units worldwide. However, right ventricular (RV) pressure overload and ACP are quantifiable without the use of PAC. Thus, most recent studies have used the echocardiographic measure of RV pressure overload to detect pulmonary vascular dysfunction.

ACP is identified on transesophageal echocardiography by a combination of RV enlargement with septal dyskinesia.\[[@ref12]\] RV dilatation is defined by an RV end diastolic area (RVEDA)/left ventricular end diastolic area (LVEDA with both measured at end diastole) ratio of 0.6.

Incidence of Acute Cor Pulmonale in Acute Respiratory Distress Syndrome {#sec1-2}
=======================================================================

Multiple studies have shown that the incidence of ACP has decreased as we have improved our ventilator management strategies. The incidence has varied between 25% and 50% in various studies.\[[@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19]\] The use of PAC to quantify transpulmonary gradient as a marker of pulmonary vascular dysfunction in ARDS has been studied retrospectively from the database of the Fluid and Catheter Treatment Trial Study by Bull *et al*.\[[@ref20]\] They documented a \>70% incidence of pulmonary vascular dysfunction among those with acute lung injury. This study also demonstrated that elevated transpulmonary gradients were independently associated with poor outcomes. Hence, now we know that pulmonary dysfunction is common and occurs in the most severe end of the spectrum of this disease. It can lead to RV dysfunction and ACP.

Does Acute Cor Pulmonale Impact Mortality in Acute Respiratory Distress Syndrome? {#sec1-3}
=================================================================================

ACP had traditionally been considered to be just a marker of severity and was thought to have no direct impact on prognosis. But recent studies have shown that it is associated with significant increase in resting heart rate, a decrease in systemic blood pressure and a greater need for hemodynamic support. It was found to be independently associated with 28-day mortality and in-hospital mortality. Other associations included one with elevated lactate levels and a more frequent requirement for prone-positioning and Nitric Oxide rescue therapy.\[[@ref18]\]

How Do Patients with Acute Respiratory Distress Syndrome Develop Acute Cor Pulmonale? {#sec1-4}
=====================================================================================

The following mechanisms have been suggested to play a crucial role in the development of ACP in ARDS:

ARDS affects not only alveoli but also the pulmonary circulation. This is due to inflammation, vasoconstriction, edema, thrombi, and vascular remodeling leading to increased pulmonary vascular resistance.\[[@ref21]\]The increase in pulmonary artery pressure may be ascribed to unadapted positive pressure ventilation, inducing a deleterious competition between the distending pressure of alveoli and the flow into pulmonary capillaries. Thus, it has been observed that with a PEEP \>10 cm H~2~O, the pulmonary artery occlusion pressure (which under normal circumstances is equal to left ventricular end diastolic pressure \[LVEDP\]) is higher than the LVEDP. To understand this concept, we will have to review the relationship between lung stretch and pulmonary vascular resistance. This is clearly explained by the Whittenberger curve \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref22][@ref23][@ref24]\] This describes a biphasic response in pulmonary vascular resistance as we inflate the alveoli from complete collapse to over-inflation. The vascular resistance is least in a segment of the curve where the normal lungs function. Both over-distension of the alveoli and atelectasis have the same effect on vascular resistancePermissive hypercapnia may also have a role to play by causing hypercapnic vasoconstriction in ARDS.

![U-shaped relationship between pulmonary vascular resistance and lung stress with lowest pulmonary vascular resistance at function residual capacity. Resistance increases as there is over-distension of alveoli or atelectasis. This was described by Whittenberger *et al.*](IJCCM-19-606-g001){#F1}

What are the Factors that Impact Acute Cor Pulmonale? {#sec1-5}
=====================================================

Boissier *et al*. published a study of 226 moderate to severe ARDS and identified that infection as a cause of ARDS and elevated driving pressures (ΔP) were independently associated with the development of ACP on multivariate analysis.\[[@ref18]\] In fact, driving pressures have very recently been described as the best predictor of survival in patients with ARDS. The authors defined driving pressure as Δ*P* = V~T~/C~RS~ where V~T~ is the tidal volume and C~RS~ is the compliance of the respiratory system.\[[@ref25]\] Other studies have indicated hypercapnia, PaCO~2~ \>60 as an independent risk factor for development of ACP.\[[@ref13][@ref19]\] Higher plateau pressures, particularly above 35 mm of Hg, have also been noted to be associated with ACP.\[[@ref13]\]

What Can We Do to Reduce Right Sided Pressure in Acute Respiratory Distress Syndrome? {#sec1-6}
=====================================================================================

Based on the above discussion, any maneuver that reduces PEEP, PaCO~2~, and driving pressure keeping plateau pressures as low as possible should theoretically help to achieve that goal. In practice, these concepts are often difficult to implement. In order to optimize oxygenation, intensivists will often accept a higher PaCO~2~. Apart from lung-protective ventilation, the only other ventilation strategy that has shown significant reproducible improvements in oxygenation and mortality from ARDS is prone-positioning.\[[@ref6]\] Prone-positioning by itself also gives us the opportunity to reduce the need for higher PEEP, allows us to target a lower plateau pressure and has been shown to reduce RV dilation/ACP.\[[@ref14]\] It has been demonstrated that prone-positioning in severe ARDS is associated with statistically significant reductions in PaCO~2~ and plateau pressures, and improvement in P/F ratio. Interestingly, the ratio between the RVEDA and LVEDA was significantly reduced in only those who have both severe ARDS and ACP. Similar improvement in RV dimensions also occurred in those without ACP on prone-positioning, but the change was not statistically significant. Significant improvement in left ventricular ejection fraction with prone-positioning was also seen in the group of patients that had ACP.\[[@ref14]\]

Conclusion {#sec1-7}
==========

Even though the occurrence of ACP has diminished in the modern era of low-tidal volume ventilation, it is still seen in a significant proportion of patients with severe ARDS. The good news is that significant improvement of RV function may be achieved in all patients with ACP in severe ARDS who undergo prone-positioning. Early identification of right heart pressure overload and ACP is crucial, particularly in view of data that indicate that ACP impacts mortality in ARDS. Fortunately, we do not need PACs to monitor pulmonary artery pressures. Instead, echocardiography can help us to identify patients with ACP. Transesophageal echocardiography is a sensitive modality used to evaluate the right ventricle and septal dyskinesia. Thus, based on recent studies, the French Society of Intensive Care Medicine has recognized the need for monitoring the right ventricle in patients with ARDS.\[[@ref26]\]

The crucial question that still needs to be answered is whether we should consider prone-positioning patients with ACP, who do not have a P/F \<150 mm of Hg? It is also necessary to consider whether it is time to implement a stricter plateau pressure limits in all patients with ARDS irrespective of whether they have ACP or not.

Finally, we need to consider the need to implement a "right ventricle-protective strategy" for ventilation. This involves a stricter control of plateau pressures (preferably below 27 mm of Hg), keeping PaCO~2~ below 60 mm of Hg and restricting driving pressures to as low as possible.\[[@ref27][@ref28]\] Prone-positioning carries the greatest potential of transforming this concept to life.

Surely, a lot of research is still needed to determine the exact pathways by which ARDS affects the pulmonary vasculature, and subsequently worsens RV function. Assessment of pulmonary vascular resistance and right ventricular dysfunction in severe ARDS may open a new frontier in our fight against ARDS.
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